Weekly medicine versus placebo for overweight or obesity in Chinese adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3, randomized trial compares berobenatide to placebo to determine safety and effectiveness for adults in China who are overweight or have obesity. Eligible participants have BMI 28 or higher (or BMI 24–27.9 with at least one weight-related condition) and may include individuals with type 2 diabetes under specific HbA1c ranges. Participants will be randomly assigned to receive either berobenatide or placebo and will be monitored over time for changes in body weight and overall health. Key exclusion criteria include recent weight changes, Type 1 diabetes, history of pancreatitis, and certain thyroid-related cancer risks, among others. Conducted at multiple Chinese hospitals, the study is sponsored by Pfizer with local collaboration.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults ≥18 years of age.
* BMI ≥28 kg/m²; or BMI ≥24 kg/m² and \<28 kg/m² with at least one weight-related comorbidity.
* Participants with T2D must have HbA1c 6.5% to 10.0%.
* At least one prior unsuccessful dietary weight-loss attempt.

Exclusion Criteria:

* Significant recent weight change (\>5% within 3 months).
* Type 1 diabetes mellitus.
* History of pancreatitis.
* Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple endocrine neoplasia type 2 (MEN2).
* Recent bariatric surgery or obesity procedures.
* Pregnancy or breastfeeding.

Where it's running

• The Second People's Hospital of Hefei
  Hefei, Anhui, China Recruiting
• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting
• Beijing Friendship Hospital
  Beijing, Beijing Municipality, China Recruiting
• Beijing Pinggu Hospital
  Beijing, Beijing Municipality, China Recruiting
• Beijing Tsinghua Changgung Hospital
  Beijing, Beijing Municipality, China Recruiting
• Chongqing People's Hospital
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

• FutureShape Family: a family-based weight-management program with semaglutide for children and parents

  This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.

  Recruiting Phase 4 University of Copenhagen · Copenhagen · NCT07872904

• Home self-administration of a weight-management medicine with an autoinjector in adults who are overweight or obese

  This study tests whether adults who are overweight or have obesity can successfully self-administer maridebart cafraglutide at home using an autoinjector.

  Recruiting at 25 sites Phase 3 Amgen · San Diego, California and 24 other locations · NCT07871409

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.